Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
BBC News - Friday, 15 November, 2002
The treatment is being supplied initially to those considered most at risk of developing full-blown Aids.
AngloGold estimates that up to 30% of its 40,000 workforce is infected with the virus.
Its parent company Anglo American said in August it would make anti-Aids treatment available to all its South African workers.
South African diamond mining company De Beers made a similar announcement shortly afterwards.
Although the price of such drugs is falling, treatment is still not available to the general public in South Africa's state-run hospitals and clinics.
South Africa has one of the highest infection rates in the world, with an estimated one in nine of its population of 42 million declared HIV-positive.
Counselling
Three employees received their first prescriptions for the so-called triple cocktail drugs - the potentially life-saving but expensive and complicated therapy - at the West Wits and Vaal River gold mines.
"We expect a steady inflow of more patients over the next few months", AngloGold HIV/Aids manager Petra Kruger said.
Initially, about 200 volunteers are to take part in the scheme and will be monitored.
They receive counselling about the treatment and its implications before they have to decide whether to go ahead.
It is proposed that the scheme will be expanded to all eligible patients who want it from April next year.
The company believes that not all who are HIV positive would need the drugs immediately, and not all staff would want to be tested.
"For society's sake, we hope others follow us," AngloGold Chief Executive Officer Bobby Godsell said.
Cost-effective
The cost per day to the company for the triple cocktail therapy is reported to be between two and three dollars per patient.
An earlier study by the company suggested that treatment would add $4-6 - or up to 2% - to the cost of producing an ounce of gold.
But it warned that the cost of the disease would rise to $9 per ounce if no action were taken.
021115
BB021108
Copyright © 2002 - BBC. Reproduction of this article (other than one copy for personal reference) must be cleared through the BBC.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.